Rita Nanda to Class I Phosphatidylinositol 3-Kinases
This is a "connection" page, showing publications Rita Nanda has written about Class I Phosphatidylinositol 3-Kinases.
Connection Strength
0.365
-
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 05 01; 26(9):2111-2123.
Score: 0.167
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.144
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
Score: 0.054